Regeneron Pharmaceuticals is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines for serious medical conditions. The company is renowned for its cutting-edge research in areas such as genetics, biochemistry, and biology, which has led to the development of a range of therapies for diseases including cancer, eye disorders, and inflammatory conditions. Regeneron's commitment to scientific advancement and collaboration propels its pipeline of novel treatments, aimed at improving patient outcomes and addressing unmet medical needs on a global scale. Read More
Adam Kovalčík, 19, receives $100,000 Top Award for his development of a medicine that can stop viruses from copying genes and controlling infections at the world’s largest pre-college STEM competition in Columbus, Ohio
While the Nasdaq 100 (^NDX) is filled with cutting-edge technology and consumer companies, not all are on solid footing.
Some are dealing with declining demand, high costs, or regulatory pressures that could limit future upside.
Federal court jury found Amgen liable for violating antitrust and tort laws by using cross-therapeutic bundled rebates to prevent Praluent® (alirocumab) from competing in the market
Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.
Biotech company Regeneron (NASDAQ:REGN) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling 3.7% year on year to $3.03 billion. Its non-GAAP profit of $8.22 per share was 3% below analysts’ consensus estimates.
What Happened: On Sunday, President Donald Trump announced on Truth Social that he plans to sign what he called the "most consequential executive order" in U.S. history, aimed at lowering prescription drug prices.
Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential.
However, it’s worth remembering that analysts rarely issue sell ratings, partly because their firms often seek other business from the same companies they cover.
A surplus of cash can mean financial stability, but it can also indicate a reluctance (or inability) to invest in growth.
Some of these companies also face challenges like stagnating revenue, declining market share, or limited scalability.
Curious about the top performers within the S&P500 index in the middle of the day on Thursday? Dive into the list of today's session's top gainers and losers for a comprehensive overview.
Curious about the market action on Thursday? Dive into the US markets to explore the gap up and gap down stocks in the S&P500 index during today's session.
